Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis

NCT01671072 is registered in ClinicalTrials.gov with Kolon Life Science as lead sponsor.

NCT NCT01671072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01671072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis
Lead sponsor
Kolon Life Science
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
January 31, 2013
Enrollment
54 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative arthritis